Patent ID: 11965024
Assignee: JANSSEN BIOTECH, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 29:
30. The multispecific antibody of claim 9, wherein the second binding domain that binds PSMA comprises:
(i) (a) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequence of the VH CDR1, the VH CDR2, and the VH CDR3, respectively, of a VH having the amino acid sequence of SEQ ID NO:730; and (b) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having the amino acid sequence of the VL CDR1, the VL CDR2, and the VL CDR3, respectively, of a VL having the amino acid sequence of SEQ ID NO:731;
(ii) (a) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequence of the VH CDR1, the VH CDR2, and the VH CDR3, respectively, of a VH having the amino acid sequence of SEQ ID NO:732; and (b) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having the amino acid sequence of the VL CDR1, the VL CDR2, and the VL CDR3, respectively, of a VL having the amino acid sequence of SEQ ID NO:733;
(iii) (a) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequence of the VH CDR1, the VH CDR2, and the VH CDR3, respectively, of a VH having the amino acid sequence of SEQ ID NO:734; and (b) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having the amino acid sequence of the VL CDR1, the VL CDR2, and the VL CDR3, respectively, of a VL having the amino acid sequence of SEQ ID NO:735;
(iv) (a) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequence of the VH CDR1, the VH CDR2, and the VH CDR3, respectively, of a VH having the amino acid sequence of SEQ ID NO:736; and (b) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having the amino acid sequence of the VL CDR1, the VL CDR2, and the VL CDR3, respectively, of a VL having the amino acid sequence of SEQ ID NO:737; or
(v) (a) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequence of the VH CDR1, the VH CDR2, and the VH CDR3, respectively, of a VH having the amino acid sequence of SEQ ID NO:899; and (b) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having the amino acid sequence of the VL CDR1, the VL CDR2, and the VL CDR3, respectively, of a VL having the amino acid sequence of SEQ ID NO:900.